0001193125-24-037535.txt : 20240215 0001193125-24-037535.hdr.sgml : 20240215 20240215160636 ACCESSION NUMBER: 0001193125-24-037535 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240215 ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERU INC. CENTRAL INDEX KEY: 0000863894 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 391144397 STATE OF INCORPORATION: WI FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13602 FILM NUMBER: 24643821 BUSINESS ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 BUSINESS PHONE: 3125959123 MAIL ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 FORMER COMPANY: FORMER CONFORMED NAME: FEMALE HEALTH CO DATE OF NAME CHANGE: 19960205 FORMER COMPANY: FORMER CONFORMED NAME: WISCONSIN PHARMACAL COMPANY INC DATE OF NAME CHANGE: 19920703 8-K 1 d769876d8k.htm 8-K 8-K
false 0000863894 0000863894 2024-02-15 2024-02-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 15, 2024

 

 

VERU INC.

(Exact name of registrant as specified in its charter)

 

 

 

Wisconsin   1-13602   39-1144397
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127

Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (305) 509-6897

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.01 par value per share   VERU   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 4.02

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

(a) On February 15, 2024, the Audit Committee of the Board of Directors of Veru Inc. (the “Company”), based on the recommendation of management, concluded that the Company’s previously issued consolidated financial statements as of and for the year ended September 30, 2023 (the “Prior Financial Statements”) should no longer be relied upon due to errors in overestimating certain research and development expenses associated with the Company’s projects with third-party service providers and the accounting for these expenses. The Company records estimated expenses of research and development activities conducted by third-party service providers based on factors such as estimates of the work completed as provided to the Company by confirmations by such third-party service providers and provisions within agreements with such third-party service providers such as scope of work, payment, timeline and similar provisions. The Company’s estimated research and development expenses recorded were higher than the actual expenses that were incurred. The net result of these research and development estimated expenses being recorded at too high of an amount is that the Company’s cash on hand is expected to last longer than initially stated. The Company is evaluating the impact the error has on previous fiscal periods, which also could include the audited financial statements as of and for the year ended September 30, 2022, as well as the unaudited quarterly financial statements within the years ended September 30, 2023 and 2022.

The Company is evaluating the impact of these matters on previous fiscal years and quarters to determine which financial statements in addition to the Prior Financial Statements will need to be restated, and intends to file with the Securities and Exchange Commission (the “SEC”) one or more amended periodic reports for the financial statements the Company determines to restate as soon as practicable.

The Audit Committee of the Company’s Board of Directors has discussed the matters disclosed in this Current Report on Form 8-K with RSM US LLP, the Company’s independent registered public accounting firm.

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are often, but are not always, made through the use of words or phrases such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue,” and similar expressions, or the negative of these terms, or similar expressions. These forward-looking statements include, but are not limited to, statements regarding the expectations, hopes, beliefs, intentions or strategies of the Company regarding the future including, without limitation, statements regarding: (i) the timing of the Company’s determination of which financial statements in addition to the Prior Financial Statements will need to be restated and the filing of any amended periodic reports with the SEC, and the risk that the time necessary to make such determination will cause the Company to not be timely in its filings with the SEC which could affect its eligibility to use Form S-3; and (ii) the potential impacts of items discussed in this Current Report on Form 8-K on the Company’s business, results of operations, cash flows, liquidity, cash burn, financial condition and ability to execute its strategic business plan. These statements involve estimates, assumptions, risks and uncertainties which could cause actual results to differ materially from those expressed in them, including: the risk that the Company may identify material weaknesses related to the errors described in this Current Report on Form 8-K and related deficiencies in the Company’s disclosure controls and procedures, and that the accuracy and timing of the Company’s financial reporting may be adversely affected; and the risk that investors may lose confidence in the accuracy and completeness of the Company’s financial reports, which could harm the Company’s reputation, cause the market price of the Company’s common stock to decline, subject the Company to sanctions or investigations by the SEC or other regulatory authorities, and adversely impact the Company’s ability to source external financing for the Company’s capital needs on acceptable terms or at all. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended September 30, 2023 and other documents filed by the Company from time to time with the SEC. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 15, 2023   VERU INC.
    By:  

/s/ Michele Greco

      Michele Greco
     

Chief Financial Officer and

Chief Administrative Officer

 

3

EX-101.SCH 2 veru-20240215.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 veru-20240215_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 veru-20240215_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 15, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000863894
Document Type 8-K
Document Period End Date Feb. 15, 2024
Entity Registrant Name VERU INC.
Entity Incorporation State Country Code WI
Entity File Number 1-13602
Entity Tax Identification Number 39-1144397
Entity Address, Address Line One 2916 N. Miami Avenue
Entity Address, Address Line Two Suite 1000
Entity Address, City or Town Miami
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33127
City Area Code (305)
Local Phone Number 509-6897
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value per share
Trading Symbol VERU
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d769876d8k.htm veru-20240215.xsd veru-20240215_lab.xml veru-20240215_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d769876d8k.htm": { "nsprefix": "veru", "nsuri": "http://verupharma.com/20240215", "dts": { "inline": { "local": [ "d769876d8k.htm" ] }, "schema": { "local": [ "veru-20240215.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "veru-20240215_lab.xml" ] }, "presentationLink": { "local": [ "veru-20240215_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-15_to_2024-02-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d769876d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-15_to_2024-02-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d769876d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://verupharma.com//20240215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001193125-24-037535-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-037535-xbrl.zip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end XML 15 d769876d8k_htm.xml IDEA: XBRL DOCUMENT 0000863894 2024-02-15 2024-02-15 false 0000863894 8-K 2024-02-15 VERU INC. WI 1-13602 39-1144397 2916 N. Miami Avenue Suite 1000 Miami FL 33127 (305) 509-6897 false false false false Common Stock, $0.01 par value per share VERU NASDAQ false